Anti-Thymocyte Globulin Treatment Augments 1,25-Dihydroxyvitamin D3 Serum Levels in Patients Undergoing Hematopoietic Stem Cell Transplantation

URN to cite this document:: urn:nbn:de:bvb:355-epub-541652
DOI to cite this document:: 10.5283/epub.54165

Matos, Carina

; Peter, Katrin

; Weich, Laura ; Peuker, Alice ; Schoenhammer, Gabriele ; Roider, Tobias

; Ghimire, Sakhila ; Babl, Nathalie ; Decking, Sonja ; Güllstorf, Martina ; Kröger, Nicolaus ; Hammon, Kathrin ; Herr, Wolfgang ; Stark, Klaus ; Heid, Iris M. ; Renner, Kathrin

; Holler, Ernst ; Kreutz, Marina

License: Creative Commons Attribution 4.0
PDF - Published Version
(11MB)

Date of publication of this fulltext: 09 May 2023 05:39

Alternative links to fulltext:DOI Publisher

Details

Preview

Indexed in

Export bibliographical data

Abstract

Application of anti-thymocyte globulin (ATG) is a widely used strategy for the prevention of graft-versus-host disease (GvHD). As vitamin D3 serum levels are also discussed to affect hematopoietic stem cell transplantation (HSCT) outcome and GvHD development, we analysed a possible interplay between ATG treatment and serum levels of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 in 4 HSCT ...